Quantitative evaluation of polymer gel dosimeters by broadband ultrasound attenuation

Ultrasound has been examined previously as an alternative readout method for irradiated polymer gel dosimeters, with authors reporting varying dose response to ultrasound transmission measurements. In this current work we extend previous work to measure the broadband ultrasound attenuation (BUA) response of irradiated PAGAT gel dosimeters, using a novel ultrasound computed tomography system

U and Th content in the Central Apennines continental crust: a contribution to the determination of the geo-neutrinos flux at LNGS

The regional contribution to the geo-neutrino signal at Gran Sasso National Laboratory (LNGS) was determined based on a detailed geological, geochemical and geophysical study of the region. U and Th abundances of more than 50 samples representative of the main lithotypes belonging to the Mesozoic and Cenozoic sedimentary cover were analyzed. Sedimentary rocks were grouped into four main "Reservoirs" based on similar paleogeographic conditions and mineralogy. Basement rocks do not outcrop in the area. Thus U and Th in the Upper and Lower Crust of Valsugana and Ivrea-Verbano areas were analyzed. Based on geological and geophysical properties, relative abundances of the various reservoirs were calculated and used to obtain the weighted U and Th abundances for each of the three geological layers (Sedimentary Cover, Upper and Lower Crust). Using the available seismic profile as well as the stratigraphic records from a number of exploration wells, a 3D modelling was developed over an area of 2^{\circ}x2^{\circ} down to the Moho depth, for a total volume of about 1.2x10^6 km^3. This model allowed us to determine the volume of the various geological layers and eventually integrate the Th and U contents of the whole crust beneath LNGS. On this base the local contribution to the geo-neutrino flux (S) was calculated and added to the contribution given by the rest of the world, yielding a Refined Reference Model prediction for the geo-neutrino signal in the Borexino detector at LNGS: S(U) = (28.7 \pm 3.9) TNU and S(Th) = (7.5 \pm 1.0) TNU. An excess over the total flux of about 4 TNU was previously obtained by Mantovani et al. (2004) who calculated, based on general worldwide assumptions, a signal of 40.5 TNU. The considerable thickness of the sedimentary rocks, almost predominantly represented by U- and Th- poor carbonatic rocks in the area near LNGS, is responsible for this difference.Comment: 45 pages, 5 figures, 12 tables; accepted for publication in GC

Measurement of Directional Wave Spectra Using Aircraft Laser Altimeters

A remote sensing method to measure directional oceanic surface waves by three laser altimeters on the NOAA LongEZ aircraft is investigated. To examine feasibility and sensitivity of the wavelet analysis method to various waves, aircraft motions, and aircraft flight directions relative to wave propagation directions, idealized surface waves are simulated from various idealized aircraft flights. In addition, the wavelet analysis method is also applied to two cases from field measurements, and the results are compared with traditional wave spectra from buoys. Since the wavelet analysis method relies on the “wave slopes” measured through phase differences between the time series of the laser distances between the aircraft and sea surface at spatially separated locations, the resolved directional wavenumber and wave propagation direction are not affected by aircraft motions if the resolved frequencies of the aircraft motion and the wave are not the same. However, the encounter wave frequency, which is directly resolved using the laser measurement from the moving aircraft, is affected by the Doppler shift due to aircraft motion relative to wave propagations. The wavelet analysis method could fail if the aircraft flies in the direction such that the aircraft speed along the wave propagation direction is the same as the wave phase speed (i.e., the aircraft flies along wave crests or troughs) or if two waves with different wavelengths and phase speed have the same encountered wavelength from the aircraft. In addition, the data noise due to laser measurement uncertainty or natural isotropic surface elevation perturbations can also affect the relative phase difference between the laser distance measurements, which in turn affects the accuracy of the resolved wavenumber and wave propagation direction. The smallest waves measured by the lasers depend on laser sampling rate and horizontal distances between the lasers (for the LongEZ this is 2 m). The resolved wave direction and wavenumber at the peak wave from the two field experiments compared well with on-site buoy observations. Overall, the study demonstrates that three spatially separated laser altimeters on moving platforms can be utilized to resolve two-dimensional wave spectra

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

CLUSTER: a high frequency H-mode coupled cavity linac for low and medium energies

We propose an innovative linear accelerating structure, particularly suited for hadrontherapy applications. Its two main features are compactness and good power efficiency at low beam velocities: the first is achieved through a high working frequency and a consequent high accelerating gradient, the second is obtained by coupling several H-mode cavities together. The structure is called CLUSTER, which stands for "Coupled-cavity Linac USing Transverse Electric Radial field". In order to compare the performance of this structure with other hadrontherapy linac designs involving high frequencies, a conceptual study has been performed for an operating frequency of 3 GHz. Moreover a proof of principle has been obtained through RF measurements on a prototype operating at 1 GHz. An accelerator complex using a CLUSTER linac is also considered for protontherapy purposes. The whole complex is called cyclinac and is composed of a commercial cyclotron injecting the beam in a high-frequency linac